Viela Bio, Mitsubishi Tanabe to co-develop, commercialize autoimmune disease drug in Japan and nine Asia regions
Mitsubishi Tanabe will lead the development and commercialization of inebilizumab in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, Philippines, Singapore, and Taiwan.
18% GST on biotech research services removed
Bangalore, 21 September 2018: The government has removed the 18% GST ( goods and services tax) levied on research services provided to foreign companies by biotech companies based in India. This was a major un-competitive factor making Indian biotech services uncompetitive. ABLE has been championing the need for this exemption for the last 18 months.
ABLE suggests key changes in ICMR gene therapy guidelines
While welcoming the comprehensive Draft Guidelines for Gene Therapy Product Development and Clinical Trials announced by the Indian Council of Medical Research (ICMR), the Association of Biotechnology Led Enterprises(ABLE) has suggested some key changes to be incorporated in the final guidelines.
India joins the Global Antimicrobial Resistance Research and Development Hub
India has joined the Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub as a new member. This was announced On September 12thby the Department of Biotechnology, Ministry of Science & Technology in New Delhi.